It may be beneficial for clinicians to conduct clinical trials on new therapeutic modalities in RN after radiotherapy for NPC with an elevated ApoB/ApoA1 ratio, and direct personalized treatment strategies. This evidence concerns the gene APOB and nasopharyngeal carcinoma.